Teledoc (TDOC), which just acquired Catapult Health, is using technology the “right” way, by cutting costs, improving care, and expanding margins, all while making money, Citron Research says in a new note. While telemedicine has slowed, the firm argues that Teledoc is becoming a lean, high margin business that companies like CVS (CVS) or Amazon (AMZN) “would love to own.” Citron believes the market is “sleeping” on Teladoc, and that once the market catches up, the stock should rerate higher.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc price target raised to $11.50 from $10.50 at BofA
- M&A News: Teladoc Health (NASDAQ:TDOC) To Buy Catapult Health
- Teladoc call volume above normal and directionally bullish
- Teladoc Health to acquire Catapult Health in all-cash transaction for $65M
- Teladoc price target raised to $12 from $11 at RBC Capital